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Edited by Masayuki MiyasakaAbstract MyD88 is a cytoplasmic adaptor protein that is crit-
ical for Toll-like receptor (TLR) signaling. The subcellular local-
ization of MyD88 is characterized as large condensed forms in
the cytoplasm. The mechanism and signiﬁcance of this localiza-
tion with respect to the signaling function, however, are currently
unknown. Here, we demonstrate that MyD88 localization de-
pends on the entire non-TIR region and that the correct cellular
targeting of MyD88 is indispensable for its signaling function.
The Toll-interleukin I receptor-resistance (TIR) domain does
not determine the subcellular localization, but it mediates inter-
action with speciﬁc TLRs. These ﬁndings reveal distinct roles for
the TIR and non-TIR regions in the subcellular localization and
signaling properties of MyD88.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Toll-like receptors (TLRs) are key regulators in host defense
mechanisms against infectious microorganisms [1]. More than
10 TLRs have been identiﬁed in mammals, all of which recog-
nize highly conserved molecular structures in pathogens, rang-
ing from bacterial cell-surface components to viral genomes.
Ligand binding to a TLR initiates the recruitment of the
Toll-interleukin I receptor-resistance (TIR) domain-containing
adaptor proteins (TIR adaptors) to the cytoplasmic TIR do-
main of an activated TLR. TIR adaptors then initiate signaling
events, eventually leading to the activation of the NF-jB, AP-
1, and interferon regulatory factor (IRF) families of transcrip-
tion factors, which induce the expression of genes involved in
host defense against infection [2].
Four diﬀerent TIR adaptors have been identiﬁed in mam-
mals: MyD88, TIRAP/Mal, TRIF/TICAM1, and TRAM/TI-
CAM2 [2]. MyD88 and TRIF play an essential role inAbbreviations: CFP, cyan ﬂuorescent protein; CTXb, cholera toxin
subunit b; DD, death domain; TIR, Toll-interleukin I receptor-
resistance; TLR, Toll-like receptor; YFP, yellow ﬂuorescent protein;
INT, Intermediate region
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doi:10.1016/j.febslet.2007.06.008downstream signaling, whereas TIRAP and TRAM may act
to bridge the interaction of MyD88 and TRIF with speciﬁc
TLRs. MyD88 is the ﬁrst identiﬁed TIR adaptor that is
essential for most TLR, IL-1 receptor, and IL-18 receptor
signaling [3–7]. MyD88 is a protein of 296 amino acids and
is composed of an N-terminal short region (N), a death do-
main (DD), an intermediate region (INT), and a C-terminal
TIR domain. Previous research indicates that the TIR do-
main interacts with TLRs, whereas the DD is involved in
downstream signaling. Several groups have reported the dis-
tinct subcellular localization of MyD88, which is character-
ized by condensed particles scattered throughout the cytosol
[8–11]. Previous studies using CFP-YFP FRET analysis re-
port a physical interaction between MyD88 and IRF-7 in
these condensed particles [9,12]. Therefore, this distinct local-
ization may be important for the signaling function of
MyD88. However, the mechanism by which this localization
is achieved is unknown, and its signiﬁcance with respect to
the function and structural features of MyD88 have not been
studied in depth.
Each TIR adaptor interacts with speciﬁc TLRs and TIR
adaptors. For example, MyD88 associates with all TLRs ex-
cept TLR3, whereas TRIF only associates with TLR3 and
TLR4. Furthermore, MyD88 and TRIF speciﬁcally interact
with TIRAP and TRAM, respectively. There may be two fac-
tors that determine the speciﬁc partners for MyD88: a
mechanical factor (e.g., speciﬁc TIR–TIR domain interaction)
or a spatiotemporal factor (e.g., the distinct subcellular distri-
butions of TLRs and TIR adaptors). However, the mecha-
nism underlying the speciﬁcity of TLR–TIR adaptor and
TIR adaptor–TIR adaptor interaction remains poorly under-
stood.
Here, we report distinct roles for TIR and non-TIR regions
with respect to the intracellular targeting of MyD88 and the
interaction of MyD88 with speciﬁc TLRs and TIR adaptors.
We found that the entire non-TIR region is responsible for
the distinct subcellular localization of MyD88, and the correct
cellular targeting of MyD88 is critical to its signaling function.
In contrast, the TIR domain plays an essential role in deter-
mining the speciﬁcity of the MyD88–TLR interaction, whereas
the speciﬁcity of the MyD88–TIRAP interaction was indepen-
dent of the conformation of the TIR domain. These results not
only describe the distinct roles of TIR and non-TIR regions in
the subcellular localization and signaling properties of
MyD88, they also provide evidence that the diversity of TLR
signaling may be achieved by both TIR domain-dependent
and -independent mechanisms.blished by Elsevier B.V. All rights reserved.
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2.1. Reagents and cell cultures
Flagellin and CpG-B oligodeoxynucleotides [13] were purchased
from InvivoGen (San Diego, CA, USA) and Sigma Genosys (Ishikari,
Japan), respectively. Anti-a-tubulin antibody, Alexa Fluor 594- and
647-conjugated cholera toxin subunit B (CTXb), Alexa Fluor 546-con-
jugated anti-mouse IgG, Alexa Fluor 594-conjugated phalloidin, rho-
damine B-conjugated dextran (MW 10000), and LysoTracker Red
DND-99 were purchased from Invitrogen (Carlsbad, CA, USA).
Anti-KDEL antibody and anti-58K Golgi protein antibody were
purchased from Stressgen (Ann Arbor, MI, USA) and Abcam
(Cambridge, UK), respectively. Anti-GFP antibody (clone JL-8) and
NF-jB luciferase reporter construct were purchased from Clontech
(Mountain View, CA, USA). Anti-HA antibody and anti-FLAG(M2)
peroxidase conjugate were purchased from Covance (Berkeley, CA,
USA) and Sigma (St. Louis, MO, USA), respectively.
Cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) containing 10% fetal bovine serum (FBS). All HEK293T sta-
ble transformants were prepared by retroviral gene transfer as de-
scribed previously [14].2.2. DNA constructs
The TIR domain-swap mutant (TRIFTIR) was constructed by
‘‘PCR sewing’’ of cDNA corresponding to amino acids 1–160 of
mouse MyD88 and amino acids 397–534 of mouse TRIF. The result-
ing cDNA was cloned into the pMXpie-N-HA retroviral vector. The
cDNAs encoding HA-tagged mouse MyD88, HA-tagged TRIFTIR,
and FLAG-tagged mouse TIRAP were subcloned into the pMXpie
retroviral vector [15] and pEF-BOS-EX vector (a kind gift from Dr.
Shigekazu Nagata, Kyoto University [16]). The C-terminal yellow ﬂuo-
rescent protein (YFP)- or cyan ﬂuorescent protein (CFP)-tagged full-
length MyD88 (amino acids 1–296), N (amino acids 1–31), N–DD
(amino acids 1–109), N–DD–INT (amino acids 1–160), DD–INT–
TIR (amino acids 32–296), D(1–51) (amino acids 52–296), INT–TIR
(amino acids 110–296), TRIFTIR, TLR5, and TLR9 were constructed
by subcloning cDNA encoding each protein into pMXrmv5-
(G4S)3YFP or pMXrmv5-(G4S)3CFP retroviral vectors. YFP or CFP
was fused to the C-terminus of the protein of interest via a short linker
sequence [(Gly-Gly-Gly-Gly-Ser) · 3] within the vectors. YFP-tagged
TLR4 was described previously [17].2.3. Microscopy
Cell-surface staining with CTXb was performed as described previ-
ously [18]. A Z-Stack image was collected using a KEYENCE BZ-9000
ﬂuorescent microscope with step sizes of 0.2 lm.
For the staining of various subcellular markers, cells were ﬁxed and
permeabilized with Cytoﬁx/Cytoperm solution (BD Pharmingen, San
Diego, CA, USA) and then treated with anti-a-tubulin antibody
(1:200 dilution), anti-KDEL antibody (1:200 dilution), or anti-58K
Golgi protein antibody (1:250 dilution) for 1 h at 4 C, followed by
Alexa Fluor 546-conjugated anti-mouse IgG antibody (1:200 dilution)
for 30 min at 4 C or Alexa Fluor 594-conjugated phalloidin (1:40 dilu-
tion) for 20 min at room temperature. For endosome staining, cells
were treated with 1 mg/ml rhodamine B-conjugated dextran for
10 min (early endosome) or 2 h (late endosome) at 37 C [19]. For lyso-
some staining, cells were treated with LysoTracker Red DND-99
(1:20000 dilution) for 30 min at 37 C. The images were acquired using
a Bio-Rad MRC1024 laser scanning confocal microscope.2.4. Gel ﬁltration analysis
HEK293T cells stably expressing MyD88-YFP (HEK293T-
MyD88-YFP, 1 · 107) were lysed with 500 ll of lysis buﬀer (20 mM
Tris–HCl, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, and com-
plete protease inhibitor cocktail [Roche, Mannheim, Germany], pH
7.4). The lysate was centrifuged, and the supernatant was loaded
onto a Superose 6 HR10/30 column (GE Healthcare, Little Chalfont,
UK). Fractions (0.5 ml) were analyzed by immunoblotting using anti-
GFP antibody. The apparent molecular weight was evaluated after
column calibration with protein standards: thyroglobulin (669 kDa),
ferritin (440 kDa), aldolase (158 kDa), conalbumin (75 kDa), and
ovalbumin (43 kDa).2.5. Luciferase reporter assay
HEK293T cells were plated at a density of 2 · 105 cells/well in a 24-
well plate. One day after plating, the cells were transiently transfected
with 10 ng of NF-jB luciferase reporter plasmid together with 0.8 lg
of retroviral expression plasmid(s). Luciferase activity in the total cell
lysate was monitored for 24–48 h after transfection using the dual-
luciferase reporter assay system (Promega, Madison, WI, USA).2.6. Co-imunoprecipitation
Cells (2 · 106) were transiently transfected with 8 lg of pEF-BOS-
EX-based expression plasmid(s). Twenty-four hours after transfection,
cells were lysed with 600 ll of lysis buﬀer (50 mM Tris–HCl, 150 mM
NaCl, 1% Nonidet P-40, 5 mM EDTA, and protease inhibitor cocktail
[Roche], pH 7.5). The supernatants were incubated with anti-GFP
antibody for 16 h at 4 C. Protein G-Sepharose 4 Fast Flow (GE
Healthcare) was added and the samples were incubated for 4 h at
4 C. The beads were washed four times with 1 ml of lysis buﬀer, boiled
with SDS sample buﬀer, and subjected to immunoblotting using the
indicated antibodies.2.7. GST pull-down assay
GST fusion proteins were expressed in BL21-Gold bacteria by 3 h of
induction with 0.1 mM IPTG (isopropyl-b-D()-thiogalactopyrano-
side). Bacterial pellets were resuspended in buﬀer A, consisting of
5 mM dithiothreitol (DTT) and 1% Triton X-100 in phosphate-
buﬀered saline (PBS; pH 7.4). After sonication, the lysates were centri-
fuged and the supernatants were incubated with Glutathione-Sephar-
ose 4B (GE Healthcare) for 1 h at 4 C. The beads were washed ﬁve
times with 1 ml of buﬀer A and resuspended in lysis buﬀer to prepare
a 50% slurry.
HEK293TCM cells [17] stably expressing TLR4-YFP
(HEK293TCM-TLR4-YFP; 6 · 106) were transfected with 24 lg of
empty vector or pEF-BOS-EX-TIRAP-FLAG. After 48 h, lysates were
prepared, and the supernatants were incubated with 10 lg of GST fu-
sion proteins for 1 h at 4 C. The GST fusion protein-bound beads
were washed three times with lysis buﬀer, boiled with SDS sample buf-
fer, and subjected to immunoblotting using anti-FLAG antibody.3. Results and discussion
3.1. MyD88 is localized in the cytoplasm in condensed,
morphologically diverse forms
Previous studies have shown that MyD88 is present in dis-
crete foci scattered throughout the cytosol [9–11]. We also ob-
served this distinct characteristic using MyD88-YFP fusion
proteins in HEK293T cells (Fig. 1A) and bone marrow-derived
macrophages (data not shown). MyD88-YFP induced NF-jB
activation when over-expressed (Fig. 1B) and mediated TLR
signaling in a ligand-dependent manner (Fig. 5A), indicating
that the MyD88-YFP fusion protein is functional. The Z-Stack
image collected from wide-ﬁeld microscopy showed that the
MyD88-YFP signals were morphologically diverse (Fig. 1C),
belonging to one of ﬁve typical morphologies: spot, star,
string, ring, and cocoon (Fig. 1D). The over-expressed proteins
are sometimes misfolded and form aggregates in the cyto-
plasm, causing improper subcellular distribution. To rule out
the possibility that this distinct subcellular localization of
MyD88-YFP was an artifact of over-expression, we performed
gel ﬁltration analysis to fractionate lysates from HEK293T-
MyD88-YFP cells based on molecular size. MyD88-YFP,
which has a calculated molecular size of 61.8 kDa, was de-
tected in fractions numbers. 32 and 33, corresponding to
67 kDa and 132 kDa, respectively (Fig. 1E). These data indi-
cate that MyD88-YFP is present as a monomer and/or
homodimer in the cytoplasm, which is consistent with earlier
observations by Burns et al. [5], who found that MyD88 forms
Fig. 1. MyD88 is localized in the cytoplasm as large condensed forms. (A) Confocal image of HEK293T-MyD88-YFP cells stained with Alexa Fluor
594-conjugated CTXb. (B) HEK293T cells were transiently transfected with 0.8 lg of the indicated expression plasmids along with 10 ng of NF-jB
reporter construct. Luciferase activity was measured 24 h after transfection. Results are shown as the means ± standard deviation of three
independent experiments. (C) Z-Stack image of MyD88-YFP in HEK293T cells. (D) Typical morphologies of MyD88-YFP in HEK293T cells: (a)
spot; (b) star; (c) string; (d), ring; (e), cocoon. (E) HEK293T-MyD88-YFP cells were lysed and fractionated on a Superose 6 gel ﬁltration column.
MyD88-YFP was analyzed by immunoblotting using anti-GFP antibody. The elution positions of molecular weight markers (in kDa) and the protein
concentration of the eluent monitored in real-time (mAU) are indicated.
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cellular localization of MyD88-YFP is not an artifact, but in-
stead a characteristic of endogenous MyD88.
3.2. MyD88 localizes to speciﬁc intracellular organelles
Our data from microscopy and gel ﬁltration analysis suggest
that MyD88 is present in vesicle-like structures or associated
with tubular or ﬁbrillar structures. To identify the intracellular
compartments in which MyD88 is enriched, HEK293T-
MyD88-YFP cells were stained with markers for the endoplas-
mic reticulum (ER), Golgi apparatus, endosomes, and lyso-
somes. This experiment was based on observations that some
of the morphologies of MyD88-YFP are similar to the mor-
phologies of these organelles; in addition, TLRs have been
identiﬁed in these compartments [20–23]. We used the follow-
ing markers: proteins containing a C-terminal KDEL sequence
for the ER, 58K Golgi proteins for the Golgi apparatus, dex-
tran for early and late endosomes, and LysoTracker for lyso-
somes. However, no clear co-localization of MyD88-YFP
and these markers was observed (Fig. 2). We also examined
the co-localization of MyD88 with cytoskeletal proteins such
as F-actin and a-tubulin. This was based on observations that
some of the morphologies of MyD88-YFP appeared similar to
those of the cytoskeletal structures; furthermore, MyD88 isassociated with ﬁbrillar aggregates containing b-actin in the
cytoplasm [8]. However, neither F-actin (phalloidin staining)
nor a-tubulin was clearly co-localized with MyD88-YFP
(Fig. 2). These results suggest that MyD88 resides in as yet
uncharacterized organelles.
3.3. The entire non-TIR region is required for the distinct
subcellular localization of MyD88
Typical sequences for targeting proteins to intracellular
compartments, such as the KDEL sequence in ER proteins,
have not been identiﬁed in MyD88. The primary structure of
MyD88 can be divided into four regions: the N-terminal short
region (N), a death domain (DD), an intermediate region
(INT), and a TIR domain [5]. Therefore, we investigated which
regions are involved in the subcellular localization of MyD88.
We generated several truncated mutants of MyD88 and a TIR
domain-swap mutant (TRIFTIR) in which the TIR domain of
MyD88 was replaced with the corresponding region of TRIF
[24,25] (Fig. 3A). The mutant proteins fused with YFP at the
C-terminus were expressed in HEK293T cells, and the subcel-
lular localization was examined under a microscope. The
TRIFTIR mutant and the TIR domain-deleted mutant (N–
DD–INT) were localized in the cytoplasm in condensed form
(Fig. 3B). Furthermore, these mutants were clearly co-local-
Fig. 2. MyD88 resides in uncharacterized organelles in HEK293T
cells. HEK293T-MyD88-YFP cells were stained with the indicated
markers as described in Section 2. For LysoTracker staining, the cells
were counterstained with CTXb to visualize the cell surface [blue
(pseudocolor)].
Fig. 3. The entire non-TIR region is responsible for the distinct
subcellular localization of MyD88. (A) Schematic diagram of MyD88
mutant proteins. (B) Confocal images of HEK293T cells expressing the
proteins depicted in A. The images were created as described in
Fig. 1A. MyD88 and its mutant proteins are shown in green; CTXb is
shown in red. (C, D) Confocal images of HEK293T cells expressing
MyD88-CFP and TRIFTIR-YFP (C) or N–DD–INT–YFP (D). The
images were created as described in Fig. 1A. MyD88-CFP is shown in
red (pseudocolor); TRIFTIR-YFP and N–DD–INT–YFP are shown
in green; CTXb is shown is light blue (pseudocolor); co-localized
signals appear yellow.
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In contrast, all other mutants lacking a part of the non-TIR
region were diﬀusely expressed throughout the cytoplasm
and/or nucleus. These results suggest that the entire non-TIR
region plays a critical role in localizing MyD88 within the cell.
3.4. Correct cellular targeting of MyD88 is critical to the
activation of signaling events
The functional signiﬁcance of this distinct subcellular local-
ization is unclear. MyD88 associates with downstream signal-
ing molecules such as interleukin-1 receptor-associated kinase
1 (IRAK1) [3] and IRF-7 [12] through its DD. Therefore, we
used DD-containing MyD88 mutants to examine the signiﬁ-
cance of the subcellular localization in signal transduction.
MyD88 and its mutants were over-expressed in HEK293T
cells, and NF-jB activity was measured using a reporter assay.
Interestingly, the TRIFTIR and N–DD–INT mutants that
were co-localized with wild-type MyD88 induced NF-jB
activation, whereas the N-DD and DD–INT–TIR mutantsthat were diﬀusely expressed throughout the cytoplasm and
nucleus did not (Fig. 4). These results suggest that the correct
cellular localization is essential for the activation of signaling
events.3.5. The speciﬁcity of TLR-MyD88 interaction is determined by
the conformational characteristics of the TIR domain
Each TLR interacts with speciﬁc TIR adaptors, allowing









































Fig. 4. Correlation between subcellular localization of MyD88 and its
signaling function. HEK293T cells were transfected with 0.8 lg of
expression plasmids encoding the proteins depicted in Fig. 3A along
with 10 ng of NF-jB reporter construct. Luciferase activity was
measured 24 h after transfection. Results are shown as the
means ± standard deviation of three independent experiments.
T. Nishiya et al. / FEBS Letters 581 (2007) 3223–3229 3227responses to distinct infectious microorganisms [26]. There are
two factors that may determine the speciﬁcity of the TLR–TIR
adaptor interaction: the conformational characteristics of each
TIR domain (i.e., a mechanical factor) and the distinct subcel-
lular localizations of TLRs and TIR adaptors (i.e., a spatio-
temporal factor). Both TLR5 and TLR9 signaling are totally
dependent on MyD88, but not other TIR adaptors [2]. To
identify the mechanism that determines the interaction speci-
ﬁcity between these proteins, wild-type MyD88 and the TRIF-
TIR mutant were co-expressed with TLR5 or TLR9 in
HEK293T cells. The cells were stimulated with ﬂagellin for
TLR5 or CpG-B for TLR9, and NF-jB activity was measured
using a reporter assay. Ligand-dependent NF-jB activation
was observed in the cells expressing MyD88, but not in those
expressing the TRIFTIR mutant, although wild-type MyD88
and the TRIFTIR mutant show similar constitutive activities
(Fig. 5A). Given that the TRIFTIR mutant co-localizes with



































Fig. 5. The interaction of MyD88 with speciﬁc TLRs is dependent on the c
were co-transfected with 10 ng of NF-jB reporter construct and the expres
0.7 lg), MyD88 (0.1 lg), TRIFTIR (0.1 lg), TLR5-YFP (0.7 lg), and TLR9-
for vector and TLR5 or 5 lM CpG-B for TLR9 and further incubated for 1
Results are shown as the means ± standard deviation of three independ
(HEK293T-TLR5-YFP) were transfected with empty vector, MyD88-HA, o
ﬂagellin at the indicated times. Lysates were prepared, and co-immunoprecip
analyzed to conﬁrm the equivalent expression of the appropriate protein
immunoglobulin light chain of anti-GFP antibody used in the immunoprecithe interaction between MyD88 and TLR5 or TLR9 is deter-
mined by the conformational characteristics of each TIR do-
main; the TIR domain of MyD88 has a high aﬃnity for
TLR5/9, whereas the TIR domain of TRIF has low aﬃnity.
We performed co-immunoprecipitation analysis to examine
the physical interaction between TLR and MyD88. Consistent
with the results from the NF-jB reporter assay, MyD88 co-
immunoprecipitated with TLR5 in a ligand-dependent man-
ner, whereas the TRIFTIR mutant did not co-immunoprecip-
itate (Fig. 5B). These results demonstrate that the speciﬁcity of
the TLR–MyD88 interaction is determined by the conforma-
tional characteristics of each TIR domain, rather than the spa-
tiotemporal characteristics of the subcellular localization of
TLRs and MyD88.3.6. The speciﬁcity of the MyD88–TIRAP interaction is
independent of the conformational characteristics of the
TIR domain
The association of MyD88 with TLR4 is distinct from its
association with TLR5 or TLR9. TLR4 requires another
TIR adaptor, TIRAP, to associate with MyD88 and activate
the MyD88-dependent signaling pathway [27,28]. TIRAP
speciﬁcally associates with MyD88 via TIR–TIR interaction
and facilitates the delivery of MyD88 to activated TLR4
[11]. Because TIRAP forms a heterodimer with MyD88
[27,28], we expected that the speciﬁcity of the MyD88–TIRAP
interaction is also determined by the conformational charac-
teristics of each TIR domain. To test this assumption, the ef-
fect of wild-type MyD88 and the TRIFTIR mutant on
TLR4-induced NF-jB activation was examined. HEK293T
cells stably expressing CD14 and MD-2 (HEK293TCM cells
[17]) were transiently transfected with TLR4 and wild-type
MyD88 or TRIFTIR mutant, and then NF-jB activity was
measured using a reporter assay. Surprisingly, TLR4 and the
TRIFTIR mutant synergistically induced NF-jB activation;
the activity in cells co-expressing both TLR4 and the TRIF-
TIR mutant was much higher (21.7 ± 2.2-fold increase) than
the activity estimated by summing the values from cells
expressing TLR4 alone and cells expressing TRIFTIR aloneB










onformational characteristics of the TIR domain. (A) HEK293T cells
sion plasmids for the indicated combinations of empty vector (0.1 or
YFP (0.7 lg). After 24 h, the cells were treated with 100 ng/ml ﬂagellin
6 h at 37 C. NF-jB-dependent luciferase activity was then analyzed.
ent experiments. (B) HEK293T cells stably expressing TLR5-YFP
r TRIFTIR-HA. After 24 h, the cells were stimulated with 100 ng/ml
itation analysis was performed as described in Section 2. Lysates were






























































































Fig. 6. The speciﬁc interaction of MyD88 with TIRAP is independent of the conformational characteristics of the TIR domain. (A) HEK293TCM
cells [17] were co-transfected with 10 ng of NF-jB reporter construct and the expression plasmids for the indicated combinations of empty vector (0.7
or 0.8 lg), MyD88 (0.1 lg), TRIFTIR (0.1 lg), and TLR4-YFP (2 ng). After 24 h, NF-jB-dependent luciferase activity was measured. Results are
shown as the means ± standard deviation of three independent experiments. (B) GST pull-down assay. GST fusion proteins were incubated with
lysates prepared from HEK293T cells transfected with empty vector or TIRAP-FLAG. The interaction of TIRAP with GST fusion proteins was
detected by immunoblotting with anti-FLAG antibody. (C) Coomassie blue staining to detect GST-MyD88, GST-TRIFTIR, and GST proteins
puriﬁed from bacteria. (D) Lysates from 293TCM-TLR4-YFP cells transfected with the indicated expression plasmids were subjected to co-
immunoprecipitation analysis as described in Fig. 5. The asterisks next to the upper and the middle panels show the immunoglobulin light chain of
anti-HA antibody used in the immunoprecipitation.
3228 T. Nishiya et al. / FEBS Letters 581 (2007) 3223–3229(14.1 ± 2.4-fold increase). These results suggest that the TRIF-
TIR mutant mediates TLR4 signaling. To test whether the
TRIFTIR mutant is required to physically interact with TIR-
AP to mediate TLR4 signaling, we performed a GST pull-
down assay. TIRAP interacted with the GST-TRIFTIR mu-
tant more eﬃciently than with the GST-MyD88 proteins
(Fig. 6B). Coomassie blue staining conﬁrmed that the same
amounts of GST-fusion proteins were used in the assay
(Fig. 6C). Furthermore, we investigated the interaction of
TIRAP and the TRIFTIR mutant using co-immunoprecipita-
tion analysis. Consistent with the results from the GST pull-
down assay, TIRAP co-immunoprecipitated more eﬃciently
with the TRIFTIR mutant than with wild-type MyD88 in
HEK293TCM-TLR4-YFP cells (Fig. 6D). These results sug-
gest that the aﬃnity of the TIR domain of TRIF for TIRAP
may be stronger than that for MyD88. It is likely that the
MyD88–TIRAP interaction required for TLR4 signaling is
independent of the conformational characteristics of the TIR
domain.
Although our results showed a physical interaction between
the TRIFTIR mutant and TIRAP, TRIF itself does not
interact with TIRAP. Similar to TLRs, the TIR adaptors
exhibit a notably diverse subcellular distribution. TRIF is dif-
fusely expressed in the cytoplasm [12], whereas TIRAP and
TRAM are localized on or proximal to the plasma membrane
owing to their targeting motifs, which include phosphatidylin-
ositol 4,5-bisphosphate (PIP2)-binding domains and myris-
toylation sites [11,29]. Because the TRIFTIR mutant was co-
localized with MyD88 (Fig. 3C), TRIF might interact with
TIRAP if TRIF is targeted to a location in which MyD88 is
enriched.3.7. Concluding remarks
MyD88 is present in condensed, morphologically diverse
forms in the cytoplasm. Our results demonstrate that the entire
non-TIR region is suﬃcient for targeting MyD88 to as yet
uncharacterized locations within the cell, where it interacts
with signaling molecules and induces host defense responses.
Furthermore, the interaction between MyD88 and speciﬁc
TLRs is likely determined by the conformational characteris-
tics of each TIR domain, whereas the speciﬁc interaction of
MyD88 and TIRAP required for TLR4 signaling is likely
determined by other spatiotemporal factors. These distinctive
properties of the TIR and non-TIR regions are important
for inducing eﬀective immune responses via targeting MyD88
to the correct cellular location and by preventing MyD88 from
associating with inappropriate partners.Acknowledgements: This work was supported in part by Grants-in-Aid
from the Ministry of Health, Labour and Welfare of Japan (to T.
Nishiya) and the Ministry of Education, Culture, Sports, Science,
and Technology of Japan (to S. Miwa), and grants from the Smoking
Research Foundation, Japan (to S. Miwa), and the Akiyama Founda-
tion (to T. Nishiya).References
[1] Akira, S. and Takeda, K. (2004) Toll-like receptor signalling. Nat.
Rev. Immunol. 4, 499–511.
[2] Akira, S., Uematsu, S. and Takeuchi, O. (2006) Pathogen
recognition and innate immunity. Cell 124, 783–801.
[3] Wesche, H., Henzel, W.J., Shillinglaw, W., Li, S. and Cao, Z.
(1997) MyD88: an adapter that recruits IRAK to the IL-1
receptor complex. Immunity 7, 837–847.
T. Nishiya et al. / FEBS Letters 581 (2007) 3223–3229 3229[4] Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H.,
Sakagami, M., Nakanishi, K. and Akira, S. (1998) Targeted
disruption of the MyD88 gene results in loss of IL-1- and IL-18-
mediated function. Immunity 9, 143–150.
[5] Burns, K., Martinon, F., Esslinger, C., Pahl, H., Schneider, P.,
Bodmer, J.L., Di Marco, F., French, L. and Tschopp, J. (1998)
MyD88, an adapter protein involved in interleukin-1 signaling. J.
Biol. Chem. 273, 12203–12209.
[6] Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A.,
Chen, C., Ghosh, S. and Janeway Jr., C.A. (1998) MyD88 is an
adaptor protein in the hToll/IL-1 receptor family signaling
pathways. Mol. Cell 2, 253–258.
[7] Kawai, T., Adachi, O., Ogawa, T., Takeda, K. and Akira, S.
(1999) Unresponsiveness of MyD88-deﬁcient mice to endotoxin.
Immunity 11, 115–122.
[8] Jaunin, F., Burns, K., Tschopp, J., Martin, T.E. and Fakan, S.
(1998) Ultrastructural distribution of the death-domain-contain-
ing MyD88 protein in HeLa cells. Exp. Cell Res. 243, 67–75.
[9] Kawai, T., Sato, S., Ishii, K.J., Coban, C., Hemmi, H., Yamam-
oto, M., Terai, K., Matsuda, M., Inoue, J., Uematsu, S.,
Takeuchi, O. and Akira, S. (2004) Interferon-alpha induction
through Toll-like receptors involves a direct interaction of IRF7
with MyD88 and TRAF6. Nat. Immunol. 5, 1061–1068.
[10] Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T.,
Takaoka, A., Taya, C. and Taniguchi, T. (2005) Spatiotemporal
regulation of MyD88-IRF-7 signalling for robust type-I inter-
feron induction. Nature 434, 1035–1040.
[11] Kagan, J.C. and Medzhitov, R. (2006) Phosphoinositide-medi-
ated adaptor recruitment controls Toll-like receptor signaling.
Cell 125, 943–955.
[12] Honda, K., Yanai, H., Mizutani, T., Negishi, H., Shimada, N.,
Suzuki, N., Ohba, Y., Takaoka, A., Yeh, W.C. and Taniguchi, T.
(2004) Role of a transductional–transcriptional processor com-
plex involving MyD88 and IRF-7 in Toll-like receptor signaling.
Proc. Natl. Acad. Sci. USA 101, 15416–15421.
[13] Verthelyi, D., Ishii, K.J., Gursel, M., Takeshita, F. and Klinman,
D.M. (2001) Human peripheral blood cells diﬀerentially recognize
and respond to two distinct CPG motifs. J. Immunol. 166, 2372–
2377.
[14] Nishiya, T. and DeFranco, A.L. (2004) Ligand-regulated chimeric
receptor approach reveals distinctive subcellular localization and
signaling properties of the Toll-like receptors. J. Biol. Chem. 279,
19008–19017.
[15] Onishi, M., Kinoshita, S., Morikawa, Y., Shibuya, A., Phillips, J.,
Lanier, L.L., Gorman, D.M., Nolan, G.P., Miyajima, A. and
Kitamura, T. (1996) Applications of retrovirus-mediated expres-
sion cloning. Exp. Hematol. 24, 324–329.
[16] Murai, K., Murakami, H. and Nagata, S. (1998) Myeloid-speciﬁc
transcriptional activation by murine myeloid zinc-ﬁnger protein 2.
Proc. Natl. Acad. Sci. USA 95, 3461–3466.
[17] Nishiya, T., Kajita, E., Miwa, S. and Defranco, A.L. (2005) TLR3
and TLR7 are targeted to the same intracellular compartments bydistinct regulatory elements. J. Biol. Chem. 280, 37107–
37117.
[18] Nishiya, T., Kajita, E. and Miwa, S. (2006) Ligand-independent
oligomerization of TLR4 regulated by a short hydrophobic region
adjacent to the transmembrane domain. Biochem. Biophys. Res.
Commun. 341, 1128–1134.
[19] Petiot, A., Faure, J., Stenmark, H. and Gruenberg, J. (2003) PI3P
signaling regulates receptor sorting but not transport in the
endosomal pathway. J. Cell Biol. 162, 971–979.
[20] Hornef, M.W., Frisan, T., Vandewalle, A., Normark, S. and
Richter-Dahlfors, A. (2002) Toll-like receptor 4 resides in the
Golgi apparatus and colocalizes with internalized lipopolysac-
charide in intestinal epithelial cells. J. Exp. Med. 195, 559–
570.
[21] Latz, E., Schoenemeyer, A., Visintin, A., Fitzgerald, K.A.,
Monks, B.G., Knetter, C.F., Lien, E., Nilsen, N.J., Espevik, T.
and Golenbock, D.T. (2004) TLR9 signals after translocating
from the ER to CpG DNA in the lysosome. Nat. Immunol. 5,
190–198.
[22] Lee, J., Chuang, T.H., Redecke, V., She, L., Pitha, P.M., Carson,
D.A., Raz, E. and Cottam, H.B. (2003) Molecular basis for the
immunostimulatory activity of guanine nucleoside analogs: acti-
vation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 100,
6646–6651.
[23] Leifer, C.A., Kennedy, M.N., Mazzoni, A., Lee, C., Kruhlak,
M.J. and Segal, D.M. (2004) TLR9 is localized in the endoplasmic
reticulum prior to stimulation. J. Immunol. 173, 1179–1183.
[24] Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O.,
Takeda, K. and Akira, S. (2002) Cutting edge: a novel Toll/IL-1
receptor domain-containing adapter that preferentially activates
the IFN-beta promoter in the Toll-like receptor signaling. J.
Immunol. 169, 6668–6672.
[25] Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T. and
Seya, T. (2003) TICAM-1, an adaptor molecule that participates
in Toll-like receptor 3-mediated interferon-beta induction. Nat.
Immunol. 4, 161–167.
[26] Takeda, K. and Akira, S. (2005) Toll-like receptors in innate
immunity. Int. Immunol. 17, 1–14.
[27] Fitzgerald, K.A., Palsson-McDermott, E.M., Bowie, A.G., Jeﬀ-
eries, C.A., Mansell, A.S., Brady, G., Brint, E., Dunne, A., Gray,
P., Harte, M.T., McMurray, D., Smith, D.E., Sims, J.E., Bird,
T.A. and O’Neill, L.A. (2001) Mal (MyD88-adapter-like) is
required for Toll-like receptor-4 signal transduction. Nature 413,
78–83.
[28] Horng, T., Barton, G.M., Flavell, R.A. and Medzhitov, R. (2002)
The adaptor molecule TIRAP provides signalling speciﬁcity for
Toll-like receptors. Nature 420, 329–333.
[29] Rowe, D.C., McGettrick, A.F., Latz, E., Monks, B.G., Gay, N.J.,
Yamamoto, M., Akira, S., O’Neill, L.A., Fitzgerald, K.A. and
Golenbock, D.T. (2006) The myristoylation of TRIF-related
adaptor molecule is essential for Toll-like receptor 4 signal
transduction. Proc. Natl. Acad. Sci. USA 103, 6299–6304.
